MaxCyte beats EPS estimates as Akron deal lifts 2026 outlook

By Grace Kim

What did MaxCyte report?

$8.16 million in MaxCyte quarterly revenue exceeded the $7.39 million analyst consensus, while a $0.05 loss per share beat the expected $0.08 loss by $0.03. The company released its results Tuesday.

Zacks reported a negative net margin (revenue remaining after costs, expressed as a percentage of sales) of 114.77% and a negative return on equity (profit relative to shareholders’ equity) of 18.92%.

Takeaway: The quarter beat both consensus measures, although the negative margin and return show continued losses.

What does the Akron Bio acquisition add?

• MaxCyte agreed to acquire Akron Bio for $151.8 million in cash, stock and deferred payments. Management expects Akron to contribute $28 million in 2026 revenue and $7 million to $8 million in EBITDA (earnings before interest, taxes, depreciation and amortization).
• Management expects more than $60 million in combined 2026 revenue. It identified $3 million to $4 million in potential cost efficiencies and expects combined 2027 cash burn (the net use of cash) below $10 million.
• Funding will come largely from cash and new borrowings. Akron would broaden MaxCyte’s exposure across cell therapy manufacturing and more than double its addressable program base (the drug-development programs the company can serve). Limited current customer overlap offers cross-selling potential.

Takeaway: The deal raises the revenue base, but its financing mix puts cash and borrowing in focus.

How strong are growth and the 2026 outlook?

The conference call’s operating update cited third-quarter revenue of $10.2 million, up 49% year over year, with core revenue up 27%. MaxCyte raised its standalone 2026 revenue outlook to at least $34.5 million, citing stronger core performance, SPL milestones and royalties, and instrument purchases that arrived earlier than expected.

Takeaway: Stronger core performance and earlier instrument orders support a higher standalone forecast before acquired revenue enters the total.

What does Casgevy royalty revenue add?

MaxCyte reported $2 million in SPL revenue tied to milestones and royalties, including $1 million of Casgevy royalties. Management said: “Royalty revenue is beginning to become a more meaningful contributor.” Vertex reported Casgevy sales of about $99 million in the third quarter, up roughly 30% sequentially.

MaxCyte said it supports multiple pivotal trials and could see up to three approved products within 24 months. Those milestones give the royalty line a potential path to greater contribution.

Takeaway: Casgevy already supplies $1 million of royalties, and the trial pipeline could expand that contribution.

How did the shares trade?

Shares fell $0.09 on Tuesday to $1.21. Trading volume reached 2,164,543 shares, compared with an average of 1,058,393. The stock’s 50-day moving average was $1.26, and its 200-day average was $1.07.

MaxCyte’s 52-week range ran from $0.64 to $1.80. The company carried a $124.47 million market capitalization (the market value assigned to its shares), a P/E ratio (price divided by earnings per share) of -3.66 and a beta (a measure of volatility relative to the broader market) of 1.49. The negative ratio reflects negative earnings.

Takeaway: Tuesday’s $1.21 price sat below the 50-day average but above the 200-day average.

What do analysts expect?

Weiss Ratings moved MaxCyte to a “sell (e+)” rating from sell (d-) in a Wednesday, November 4 note. BTIG Research reiterated a neutral stance in a Monday, August 24 note. One analyst rates the stock Buy, one rates it Hold and one rates it Sell.

MarketBeat lists an average rating of Hold and a consensus price target of $5.00. That target compares with Tuesday’s $1.21 trading price, while the three-way analyst split shows that they do not share a single rating.

Takeaway: Ratings remain mixed, with the $5.00 consensus target well above the Tuesday trading price.

What does MaxCyte sell?

MaxCyte develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its ExPERT platform combines Flow Electroporation with specialized instruments, single-use processing assemblies, software and related support services.

Customers apply the platform in cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

Takeaway: ExPERT provides the operating base, while the Akron transaction broadens the manufacturing opportunity.